by Liam Connolly, UC Davis Credit: Unsplash/CC0 Public DomainAn international clinical trial involving UC Davis Health suggests the investigational drug Elafibranor is a potential novel treatment for patients with the rare, autoimmune disease primary biliary cholangitis. Results from the clinical trial showed significant improvements in biomarkers of disease progression. Patients also reported positive outcomes. The...
